CoChat

Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database

Open access
Chiappini, Stefania, Schifano, Fabrizio · 2018 · Journal of Clinical Psychopharmacology

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index; 3 of the 64 sources its claims cite were checked for support.

Abstract

Purpose/Background: A recent years' increase in both prescribing and availability of second-generation antipsychotics (SGAs) has been observed. According to the literature, typically made up by case studies/series, quetiapine seems to be the most commonly misused SGA, with both intranasal and intravenous intake modalities having been described. Another SGA that has been anecdotally reported to be misused is olanzapine. For these molecules, both a previous history of drug misuse and being an inmate have been described as factors associated with misuse. Hence, while providing here an updated literature review of the topic, we aimed at assessing all cases of quetiapine misuse/abuse/dependence/withdrawal as reported to the European Medicines Agency's EudraVigilance (EV) database; this was carried out in comparison with the reference drug olanzapine. Methods: All spontaneous, European Medicines Agency database reports relating to both quetiapine (2005–2016) and olanzapine (2004–2016) misuse/abuse/dependence/withdrawal issues were retrieved, and a descriptive analysis was performed. Results: From the EV database, 18,112 (8.64% of 209,571) and 4178 (7.58% of 55,100) adverse drug reaction reports of misuse/abuse/dependence/withdrawal were associated with quetiapine and olanzapine, respectively. The resulting proportional reporting ratio values suggested that the misuse/abuse–, dependence-, and withdrawal-related adverse drug reactions were more frequently reported for quetiapine (1.07, 1.01, and 5.25, respectively) in comparison with olanzapine. Conclusions: Despite data collection limitations, present EV data may suggest that, at least in comparison with olanzapine, quetiapine misuse may be a cause for concern.

Overview

CoChat Summary

TL;DR

In an EMA EudraVigilance analysis and literature review, quetiapine was associated with more misuse/abuse/dependence/withdrawal ADR reports than olanzapine, with a particularly high withdrawal PRR. The authors conclude quetiapine misuse may be a cause for concern relative to olanzapine, despite spontaneous-report limitations.

Key findings

  • From the EV database, quetiapine had 18,112 misuse/abuse/dependence/withdrawal ADRs (8.64% of 209,571 total ADRs; 884 patients) versus olanzapine with 4,178 (7.58% of 55,100; 237 patients).
  • PRR values for quetiapine versus olanzapine were 1.07 for misuse/abuse, 1.01 for dependence, and 5.25 for withdrawal.
  • Fatalities were identified in 368 quetiapine cases (45.2%; 2,979 ADRs) and 79 olanzapine cases (34.6%; 687 ADRs); the drug was reported on its own in only 5 quetiapine and 1 olanzapine case.
  • Most quetiapine ADRs were drug abuse (52.21%), drug dependence (26.43%), and substance abuse (7.6%); olanzapine ADRs were drug abuse (55.43%) and drug dependence (29.94%). Quetiapine IR formulations were involved in 2,122/2,265 (93.7%) cases where formulation was known; there were 22 quetiapine nasal insufflation and 18 parenteral/intravenous cases versus 1 and 7 for olanzapine.

Methods

  • Design: updated literature review plus descriptive analysis of spontaneous ADR reports in the EMA EudraVigilance database, comparing quetiapine with olanzapine.
  • Data: quetiapine reports from 07/2005–07/2016 and olanzapine reports from 09/2004–07/2016; SMQ “drug abuse, dependence and withdrawal” terms included dependence, drug abuse, drug dependence, drug withdrawal syndrome, intentional product misuse, substance abuse, substance dependence, and withdrawal syndrome.
  • Analysis: descriptive counts and proportional reporting ratio (PRR), where PRR >1 suggests the adverse event is more commonly reported for the drug of interest relative to the comparator.

Limitations

  • The paper states: spontaneous case reports rarely confirm causality; reporting depends on market availability/use, reaction nature, and awareness, so comparing report counts may mislead; reports likely reflect prescribed drugs only, not rogue websites or OTC availability; comparison assumes similar non-misuse AE profiles though profiles differ; global prescribing figures are unavailable; misuse/abuse/dependence/withdrawal are not the same issues and withdrawal alone does not indicate misuse/recreational value; duplicate or multiple ADRs per patient are possible; missing fields, no psychiatric/drug misuse history, and abuse/dependence diagnosis not made per international standards; PRR >1 may reflect sampling variation, reporting errors, bias, duplicates, or other causes; privacy limits disclosure.
  • The text also makes evident: no total exposure denominator was available to calculate a fatal toxicity index; EV lacked details on pre-discontinuation dosage, withdrawal symptom range/intensity/time-frame, and concurrent psychopathological conditions.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1097/jcp.0000000000000814

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

2 Valid · 2 Not valid · 35 Not checked · 55 Own results and interpretations

41 more claims

Create a free account to see all 94 claims and to verify the 61 references still open.

See all claims — free account
  • It may state two separate claims as one. 33
  • Probably not a substantial claim. 20
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

4 of 4

Citations

Cites

Show all 68 references

Research works printed but not linked: 7

  1. 2011, Abuse of second-generation antipsychotics: what prescribers need to know, Curr Psychiatry, 10, 77
  2. 2013, A case series of quetiapine addiction/dependence, Ger J Psychiatr, 16, 152
  3. 2010, Is seroquel developing an illicit reputation for misuse/abuse?, Psychiatry (Edgmont), 7, 13
  4. 2015, Abuse liability of quetiapine (Xeroquel®): analysis of the literature, Fundam Clin Pharmacol, 29, 27
  5. 2007, Letter to the editor. Quetiapine addiction?, Am J Psychiatry, 164, 1
  6. 2010, Olanzapine dependence, German J Psychiatry, 13, 51
  7. 2017, [Surveillance system on drug abuse: interest of the French national OPPIDUM program of French addictovigilance network], Therapie, 72, 491

Cited by

See all 44

Metadata

Authors
Chiappini, S., & Schifano, F.
Affiliations
University of Hertfordshire (GB)
Corresponding author
  • Chiappini, Stefania
  • Schifano, Fabrizio
Venue
Journal of Clinical Psychopharmacology
Published
2018-02
Volume
38
Issue
1
Pages
72-79
ISSN
  • 0271-0749 (ISSN-L)
  • 1533-712X
OpenAlex
W2768865188
Cited by
44
References
68
Citations by year
2026: 2 · 2025: 5 · 2024: 3 · 2023: 3 · 2022: 4 · 2021: 7 · 2020: 8 · 2019: 8 · 2018: 4
FWCI
4.07
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • University of Hertfordshire Research Archive (University of Hertfordshire) (acceptedVersion)
  • University of Hertfordshire Research Archive (University of Hertfordshire) (submittedVersion, cc-by-nc)
Funders
European Commission (JUST/2013/DPIP/AG/4823)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
Keywords
quetiapine, olanzapine, atypical antipsychotics, drug abuse, drug addiction, withdrawal, adverse drug reactions, EudraVigilance, intranasal administration, intravenous administration, pharmacovigilance
MeSH terms
Quetiapine Fumarate, Olanzapine, Adolescent, Adult, Benzodiazepines, Child, European Union, Female, Humans, Male, Middle Aged, Substance Withdrawal Syndrome, Antipsychotic Agents, Databases, Factual, Adverse Drug Reaction Reporting Systems, Substance-Related Disorders, Young Adult, Prescription Drug Misuse

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database. https://app.cochat.ai/papers/10.1097/jcp.0000000000000814
The paper
Chiappini, S., & Schifano, F. (2018). Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000000814

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.